-
Je něco špatně v tomto záznamu ?
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis
T. Yanagisawa, T. Kimura, K. Hata, S. Narita, S. Hatakeyama, K. Mori, T. Sano, T. Otsuka, Y. Iwamoto, Y. Enei, M. Nakazono, K. Sakanaka, K. Iwatani, A. Matsukawa, M. Atsuta, H. Nishikawa, S. Tsuzuki, J. Miki, T. Habuchi, C. Ohyama, SF. Shariat, S. Egawa
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-02-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-02-01 do Před 1 rokem
- MeSH
- androgeny terapeutické užití MeSH
- antagonisté androgenů terapeutické užití MeSH
- docetaxel terapeutické užití MeSH
- lidé MeSH
- nádory prostaty rezistentní na kastraci * patologie MeSH
- nádory prostaty * patologie MeSH
- nesteroidní antiandrogeny * terapeutické užití MeSH
- protokoly antitumorózní kombinované chemoterapie terapeutické užití MeSH
- retrospektivní studie MeSH
- tendenční skóre MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
PURPOSE: The aim of this study was to investigate the oncologic efficacy of combining docetaxel with androgen deprivation therapy (ADT) versus nonsteroidal antiandrogen (NSAA) with ADT in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with focus on the effect of sequential therapy in a real-world clinical practice setting. METHODS: The records of 382 patients who harbored high-volume mHSPC, based on the CHAARTED criteria, and had received ADT with either docetaxel (n = 92) or NSAA (bicalutamide) (n = 290) were retrospectively analyzed. The cohorts were matched by one-to-one propensity scores based on patient demographics. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), and time to second-line progression (PFS2) were compared. 2nd-line PFS defined as the time from CRPC diagnosis to progression after second-line therapy was also compared. RESULTS: After matching, a total of 170 patients were retained: 85 patients treated with docetaxel + ADT and 85 patients treated with NSAA + ADT. The median OS and CSS for docetaxel + ADT versus NSAA + ADT were not reached (NR) vs. 49 months (p = 0.02) and NR vs. 55 months (p = 0.02), respectively. Median time to CRPC and PFS2 in patients treated with docetaxel + ADT was significantly longer compared to those treated with NSAA (22 vs. 12 months; p = 0.003 and, NR vs. 28 months; p < 0.001, respectively). There was no significant difference in 2nd-line PFS between the two groups. CONCLUSIONS: Our analysis suggested that ADT with docetaxel significantly prolonged OS and CSS owing to a better time to CRPC and PFS2 in comparison to NSAA + ADT in high-volume mHSPC.
Department of Urology 2nd Faculty of Medicine Charles University Prague Czech Republic
Department of Urology Akita University School of Medicine Akita Japan
Department of Urology Atsugi City Hospital Kanagawa Japan
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna Austria
Department of Urology University of Texas Southwestern Medical Center Dallas TX USA
Department of Urology Weill Cornell Medical College New York NY USA
Hourani Center for Applied Scientific Research Al Ahliyya Amman University Amman Jordan
Institute for Urology and Reproductive Health Sechenov University Moscow Russia
Karl Landsteiner Institute of Urology and Andrology Vienna Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016795
- 003
- CZ-PrNML
- 005
- 20231026105534.0
- 007
- ta
- 008
- 231013s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00345-022-04030-2 $2 doi
- 035 __
- $a (PubMed)35596809
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Yanagisawa, Takafumi $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan. t.yanagisawa.jikei@gmail.com $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. t.yanagisawa.jikei@gmail.com $1 https://orcid.org/0000000274100712
- 245 10
- $a Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis / $c T. Yanagisawa, T. Kimura, K. Hata, S. Narita, S. Hatakeyama, K. Mori, T. Sano, T. Otsuka, Y. Iwamoto, Y. Enei, M. Nakazono, K. Sakanaka, K. Iwatani, A. Matsukawa, M. Atsuta, H. Nishikawa, S. Tsuzuki, J. Miki, T. Habuchi, C. Ohyama, SF. Shariat, S. Egawa
- 520 9_
- $a PURPOSE: The aim of this study was to investigate the oncologic efficacy of combining docetaxel with androgen deprivation therapy (ADT) versus nonsteroidal antiandrogen (NSAA) with ADT in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with focus on the effect of sequential therapy in a real-world clinical practice setting. METHODS: The records of 382 patients who harbored high-volume mHSPC, based on the CHAARTED criteria, and had received ADT with either docetaxel (n = 92) or NSAA (bicalutamide) (n = 290) were retrospectively analyzed. The cohorts were matched by one-to-one propensity scores based on patient demographics. Overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), including time to castration-resistant prostate cancer (CRPC), and time to second-line progression (PFS2) were compared. 2nd-line PFS defined as the time from CRPC diagnosis to progression after second-line therapy was also compared. RESULTS: After matching, a total of 170 patients were retained: 85 patients treated with docetaxel + ADT and 85 patients treated with NSAA + ADT. The median OS and CSS for docetaxel + ADT versus NSAA + ADT were not reached (NR) vs. 49 months (p = 0.02) and NR vs. 55 months (p = 0.02), respectively. Median time to CRPC and PFS2 in patients treated with docetaxel + ADT was significantly longer compared to those treated with NSAA (22 vs. 12 months; p = 0.003 and, NR vs. 28 months; p < 0.001, respectively). There was no significant difference in 2nd-line PFS between the two groups. CONCLUSIONS: Our analysis suggested that ADT with docetaxel significantly prolonged OS and CSS owing to a better time to CRPC and PFS2 in comparison to NSAA + ADT in high-volume mHSPC.
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a docetaxel $x terapeutické užití $7 D000077143
- 650 12
- $a nádory prostaty $x patologie $7 D011471
- 650 _2
- $a antagonisté androgenů $x terapeutické užití $7 D000726
- 650 12
- $a nesteroidní antiandrogeny $x terapeutické užití $7 D057466
- 650 _2
- $a androgeny $x terapeutické užití $7 D000728
- 650 12
- $a nádory prostaty rezistentní na kastraci $x patologie $7 D064129
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a tendenční skóre $7 D057216
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x terapeutické užití $7 D000971
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kimura, Takahiro $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Hata, Kenichi $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan $u Department of Urology, Atsugi City Hospital, Kanagawa, Japan
- 700 1_
- $a Narita, Shintaro $u Department of Urology, Akita University School of Medicine, Akita, Japan
- 700 1_
- $a Hatakeyama, Shingo $u Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Sano, Takayuki $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Otsuka, Takashi $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Iwamoto, Yuya $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Enei, Yuki $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Nakazono, Minoru $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Sakanaka, Keigo $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Iwatani, Kosuke $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Matsukawa, Akihiro $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Atsuta, Mahito $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Nishikawa, Hideomi $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Tsuzuki, Shunsuke $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Miki, Jun $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 700 1_
- $a Habuchi, Tomonori $u Department of Urology, Akita University School of Medicine, Akita, Japan
- 700 1_
- $a Ohyama, Chikara $u Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria $u Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia $u Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, NY, USA $u Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria
- 700 1_
- $a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, 3-19-18, Nishi-shimbashi, Minato-ku, Tokyo, 105-8471, Japan
- 773 0_
- $w MED00004739 $t World journal of urology $x 1433-8726 $g Roč. 41, č. 8 (2023), s. 2051-2062
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35596809 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026105529 $b ABA008
- 999 __
- $a ok $b bmc $g 2000375 $s 1203157
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 41 $c 8 $d 2051-2062 $e 20220521 $i 1433-8726 $m World journal of urology $n World J Urol $x MED00004739
- LZP __
- $a Pubmed-20231013
